Page 5 - Stan Erck News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novavax chief ‘not able to predict’ Australian approval date for vaccine We’re sorry, this service is currently unavailable. Please try again later. Dismiss Save Normal text size Advertisement The chief executive of coronavirus vaccine maker Novavax has admitted the company will have to delay filing for approvals of the product until July and will not put a date on when the vaccine is likely to receive the green light in Australia. The Australian government has ordered 51 million doses of the Novavax vaccine, which had been expected to start being delivered as early as Septembe...

POLITICO The most promising coronavirus vaccine you’ve never heard of Novavax’s rise comes as pressure to increase the supply of Covid-19 vaccines is growing amid concerns that unequal access globally will extend the pandemic. Swabs from patients participating in the Novavax Phase III Covid-19 clinical vaccine trial await testing in Seattle, Wash. | Karen Ducey/Getty Images Link Copied Hopes are growing that a dark-horse coronavirus vaccine from a tiny U.S. drugmaker can shore up supplies in the U.S. and globally as safety concerns and production problems shadow shots from Johnson & John...

By Carl O'Donnell April 13 (Reuters) - Novavax Inc has pushed back the timeline for hitting its production target of 150 million COVID-19 vaccine doses per month until the third quarter due to supply shortages including bags used to grow cells, a company spokeswoman told Reuters. Novavax executives had previously said full-scale vaccine production could be achieved by mid-year. The company told Reuters in January it expected to reach full production capacity by May or June. "We said during our earnings call that we expect all capacity being online by around mid-year. We're continuing to refin...

Novavax COVID-19 vaccine production set back due to supply shortages Posted 5 AprApril 2021 at 2:06pm Data released in March from the UK trial showed the vaccine to be highly effective against COVID-19. ( Print text only Cancel Novavax Inc has pushed back the timeline for hitting its production target of 150 million COVID-19 vaccine doses per month until the third quarter due to supply shortages, dealing another blow to the federal government's rollout plans. Key points: Novavax is one of three companies the federal government struck a deal with to distribute COVID-19 vaccines in Australia...

Last modified on Sat 10 Apr 2021 10.48 EDT Vaccine-makers around the world face shortages of vital components including large plastic growbags, according to the head of the firm that is manufacturing a quarter of the UK’s jab supply. Stan Erck, the chief executive of Novavax – which makes the second vaccine to be grown and bottled entirely in Britain – told the Observer that the shortage of 2,000-litre bags in which the vaccine cells were grown was a significant hurdle for global supply. His warning came as bag manufacturers revealed that some pharmaceutical firms were waiting up to 12...